KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Depreciation & Amortization (CF): 2010-2025

Historic Depreciation & Amortization (CF) for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $2.7 million.

  • Halozyme Therapeutics' Depreciation & Amortization (CF) rose 3.85% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 2.34%. This contributed to the annual value of $10.3 million for FY2024, which is 7.21% down from last year.
  • Halozyme Therapeutics' Depreciation & Amortization (CF) amounted to $2.7 million in Q3 2025, which was down 0.00% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Depreciation & Amortization (CF) registered a high of $2.9 million during Q4 2023, and its lowest value of $700,000 during Q3 2021.
  • In the last 3 years, Halozyme Therapeutics' Depreciation & Amortization (CF) had a median value of $2.7 million in 2025 and averaged $2.7 million.
  • In the last 5 years, Halozyme Therapeutics' Depreciation & Amortization (CF) fell by 18.00% in 2021 and then spiked by 231.06% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $776,000 in 2021, then skyrocketed by 231.06% to $2.6 million in 2022, then rose by 12.88% to $2.9 million in 2023, then decreased by 7.24% to $2.7 million in 2024, then climbed by 3.85% to $2.7 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $2.7 million for Q3 2025, versus $2.7 million for Q2 2025 and $2.7 million for Q1 2025.